Precigen (PGEN)
(Delayed Data from NSDQ)
$1.37 USD
+0.01 (0.37%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.37 +0.01 (0.37%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PGEN 1.37 +0.01(0.37%)
Will PGEN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PGEN
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
PGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Other News for PGEN
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
Buy Rating Affirmed for Precigen Amid Promising Clinical Data and Strong Financial Outlook
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Buy Rating Affirmed for Precigen Amid Promising Clinical Developments and Strategic FDA Alignment
PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q1 2024